Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending June 2014. The report details a specific share repurchase transaction executed on June 12, 2014, pursuant to shareholder authority granted at the Annual General Meeting on May 7, 2014.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 236,356 Ordinary Shares of 25 pence each.
- Purchase Price Range: Highest price of 1,621 pence per share; lowest price of 1,614.50 pence per share.
- Treasury Holdings (Settled): 500,172,414 shares (9.35% of total issued share capital).
- Treasury Holdings (Including Unsettled): 500,983,770 shares (10.33% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,850,697,273 shares.
Material Changes
The filing reports a reduction in outstanding shares due to the repurchase of 236,356 shares. Consequently, the percentage of shares held in Treasury increased to 10.33% of total voting rights when including unsettled purchases. No other material changes to operations or financial position are disclosed in this document.
Guidance, Outlook, and Risks
The filing contains no management guidance, outlook, risk factors, or discussion of contingencies. It is a compliance announcement confirming adherence to the Financial Conduct Authority's Disclosure and Transparency Rules regarding share buybacks.
Investor Verification Checklist
- Verify the total number of shares in issue (4,850,697,273) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the current percentage of voting rights held in Treasury (10.33% including unsettled shares).
- Review the price paid per share (1,614.50 to 1,621 pence) against market prices on June 12, 2014.
- Note that this filing does not contain financial performance data; refer to Form 20-F for comprehensive financial statements.